Arcus Biosciences Inc (RCUS)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 150,000 | 127,000 | 206,000 | 148,000 | 173,415 |
| Short-term investments | US$ in thousands | 828,000 | 632,000 | 803,000 | 351,394 | 555,231 |
| Receivables | US$ in thousands | 5,000 | 4,000 | 43,000 | 746,762 | 1,592 |
| Total current liabilities | US$ in thousands | 226,000 | 184,000 | 193,000 | 166,000 | 121,669 |
| Quick ratio | 4.35 | 4.15 | 5.45 | 7.51 | 6.00 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($150,000K
+ $828,000K
+ $5,000K)
÷ $226,000K
= 4.35
The quick ratio of Arcus Biosciences Inc has shown a positive trend over the past five years, indicating a strong ability to meet its short-term obligations using its most liquid assets. Starting at 6.00 on December 31, 2020, the ratio increased to 7.51 by December 31, 2021, reflecting a significant improvement in liquidity. However, there was a slight decline to 5.45 by December 31, 2022, and further decrease to 4.15 by December 31, 2023. The ratio saw a slight recovery to 4.35 by December 31, 2024, but still remained below the peak of 7.51. Overall, the company's quick ratio demonstrates a generally healthy liquidity position, although there has been some variability in the ability to cover short-term obligations with liquid assets over the years.
Peer comparison
Dec 31, 2024